AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10902528 — intervention group
Group type: COMPARATOR
Intervention: Conventional Lecture Hall
Number of subjects: 0
Study 8714363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordaflex 20 mg retard film coated tablets
Number of subjects: 31
Study 8714363 — intervention group
Group type: COMPARATOR
Intervention: Adalat 20 mg retard film coated tablets
Number of subjects: 31
Study 1562025 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment for a mean period of 4 months
Number of subjects: 22
Study 1562025 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 22
Study 1562025 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO treatment
Number of subjects: 22
Study 6694867 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counseling
Number of subjects: 57
Study 6694867 — intervention group
Group type: COMPARATOR
Intervention: Nurse counseling
Number of subjects: 57
Study 30296402 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (HIIE)
Number of subjects: 25
Study 30296402 — intervention group
Group type: COMPARATOR
Intervention: Control (watching a nature documentary)
Number of subjects: 25
Study 30012526 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy plus stereotactic body radiation therapy (50 Gy/4 fractions)
Number of subjects: 60
Study 30012526 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy plus 45 Gy/15 fractions
Number of subjects: 60
Study 30012526 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily chemoimmunoradiotherapy (45 Gy in twice-daily fractions)
Number of subjects: 60
Study 26521866 — intervention group
Group type: EXPERIMENTAL
Intervention: 27-gauge needle
Number of subjects: 208
Study 26521866 — intervention group
Group type: COMPARATOR
Intervention: 30-gauge needle
Number of subjects: 208
Study 25370504 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid online training module for panic disorder (PD) based on cognitive behavioral therapy, consisting of six modules over six weeks
Number of subjects: 90
Study 25370504 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group for six months
Number of subjects: 90
Study 21678089 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Innovation (IES) using audiovisual material containing real images of dissected human cadavers
Number of subjects: 303
Study 21678089 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching method
Number of subjects: 303
Study 21172765 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth intervention (Improvehealth.eu)
Number of subjects: 46
Study 21172765 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 46
Study 17365735 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch 63 mg/day
Number of subjects: 42
Study 17365735 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch 42 mg/day
Number of subjects: 42
Study 17365735 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch 21 mg/day
Number of subjects: 42
Study 17365735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 15483079 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (aromatase inhibitor)
Number of subjects: 26
Study 15483079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 11916934 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 0
Study 11916934 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study 9793699 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg
Number of subjects: 12
Study 9793699 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 12
Study 9793699 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 12
Study 9793699 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg + Diazepam 10 mg
Number of subjects: 12
Study 9793699 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg + Diazepam 10 mg
Number of subjects: 12
Study 9793699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8561268 — intervention group
Group type: COMPARATOR
Intervention: Intravenous quinine alone
Number of subjects: 24
Study 8561268 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous quinine in combination with pefloxacin
Number of subjects: 24
Study 8561268 — intervention group
Group type: COMPARATOR
Intervention: Intravenous quinine alone or in combination with pefloxacin
Number of subjects: 24
Study 2523210 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of amoxycillin/clavulanic acid (1.2 g Augmentin) at induction of anaesthesia (n = 328)
Number of subjects: 624
Study 2523210 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous infiltration of amoxycillin/clavulanic acid (1.2 g Augmentin) along the line of the proposed incision (n = 296)
Number of subjects: 624
Study 2523210 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 624
Study 31023758 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of metformin daily
Number of subjects: 150
Study 31023758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 28296139 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP and troponin I measurements at admission
Number of subjects: 1347
Study 28296139 — intervention group
Group type: COMPARATOR
Intervention: Clinical variables
Number of subjects: 1347
Study 25482305 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 500 mg of naproxen and 20 mg of esomeprazole (test formulation)
Number of subjects: 60
Study 25482305 — intervention group
Group type: COMPARATOR
Intervention: Combination of 500 mg of naproxen and 20 mg of esomeprazole (reference formulation)
Number of subjects: 60
Study 24023796 — intervention group
Group type: EXPERIMENTAL
Intervention: Scattered site Housing First (HF)
Number of subjects: 67
Study 24023796 — intervention group
Group type: EXPERIMENTAL
Intervention: Congregate Housing First (HF)
Number of subjects: 67
Study 24023796 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 67
Study 20800242 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized atrioventricular delay (171 ± 8 ms) at interventricular delay of 0 ms
Number of subjects: 20
Study 20800242 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized interventricular delay
Number of subjects: 20
Study 20800242 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized pacing
Number of subjects: 20
Study 20800242 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 20
Study 19104358 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia
Number of subjects: 77
Study 19104358 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 77
Study 16755394 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 3559
Study 16755394 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis and treatment related to depression severity
Number of subjects: 3559
Study 12752138 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band UVB (311 nm) + calcitriol (twice daily)
Number of subjects: 10
Study 12752138 — intervention group
Group type: COMPARATOR
Intervention: Narrow-band UVB (311 nm) + dithranol (once daily)
Number of subjects: 10
Study 10863060 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RTH) at a dose of 55 Gy/20 fractions/4 weeks
Number of subjects: 35
Study 10863060 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RTH) at a dose of 64 Gy/32 fractions/6.5 weeks
Number of subjects: 35
Study 10863060 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RTH)
Number of subjects: 35
Study 9197430 — intervention group
Group type: EXPERIMENTAL
Intervention: gallopamil 150 mg/day
Number of subjects: 19
Study 9197430 — intervention group
Group type: EXPERIMENTAL
Intervention: gallopamil 50 mg t.i.d. for 28 days
Number of subjects: 19
Study 9197430 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study 1443754 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program (2-day basic skills training)
Number of subjects: 266
Study 3943004 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy
Number of subjects: 293
Study 3943004 — intervention group
Group type: COMPARATOR
Intervention: Rigid sigmoidoscopy
Number of subjects: 293
Study 29754647 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth program
Number of subjects: 25
Study 29754647 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 25
Study 27706451 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental product (Perlatte(r) - Eurofarma Laboratórios S.A.)
Number of subjects: 129
Study 27706451 — intervention group
Group type: COMPARATOR
Intervention: Reference product (Lactaid(r) - McNeilNutritionals, USA)
Number of subjects: 129
Study 27706451 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 129
Study 24893872 — intervention group
Group type: EXPERIMENTAL
Intervention: Vessel-sealing devices (VSDs) - EnSeal, LigaSure, Harmonic
Number of subjects: 58
Study 24893872 — intervention group
Group type: COMPARATOR
Intervention: Control group (ligation and conventional electrocautery)
Number of subjects: 58
Study 22616409 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped instruction
Number of subjects: 27
Study 22616409 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on instruction
Number of subjects: 27
Study 22616409 — intervention group
Group type: COMPARATOR
Intervention: Control (no instruction)
Number of subjects: 27
Study 20977356 — intervention group
Group type: EXPERIMENTAL
Intervention: n-acetyl-L-carnitine
Number of subjects: 61
Study 20977356 — intervention group
Group type: EXPERIMENTAL
Intervention: lipoic acid + n-acetylcisteine (LA/NAC)
Number of subjects: 61
Study 20977356 — intervention group
Group type: COMPARATOR
Intervention: no supplementation
Number of subjects: 61
Study 18612576 — intervention group
Group type: EXPERIMENTAL
Intervention: Aftercare arm
Number of subjects: 1726
Study 18612576 — intervention group
Group type: COMPARATOR
Intervention: Outpatient arm
Number of subjects: 1726
Study 18612576 — intervention group
Group type: EXPERIMENTAL
Intervention: Both aftercare and outpatient samples
Number of subjects: 1726
Study 16094587 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopy
Number of subjects: 0
Study 16094587 — intervention group
Group type: EXPERIMENTAL
Intervention: Condylotomy
Number of subjects: 0
Study 16094587 — intervention group
Group type: EXPERIMENTAL
Intervention: Discectomy
Number of subjects: 0
Study 16094587 — intervention group
Group type: EXPERIMENTAL
Intervention: Disc repositioning
Number of subjects: 0
Study 11812667 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 50-100 mg b.i.d.
Number of subjects: 141
Study 11812667 — intervention group
Group type: COMPARATOR
Intervention: Xamoterol 100-200 mg b.i.d.
Number of subjects: 141
Study 11812667 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 141
Study 10075615 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg
Number of subjects: 234
Study 10075615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 10075615 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 234
Study 7722712 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy, high protein supplement (Atole)
Number of subjects: 663
Study 7722712 — intervention group
Group type: COMPARATOR
Intervention: Low energy supplement with no protein (Fresco)
Number of subjects: 663
Study 2201047 — intervention group
Group type: EXPERIMENTAL
Intervention: M-VAC chemotherapy
Number of subjects: 0
Study 2201047 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunological agents
Number of subjects: 0
Study 2201047 — intervention group
Group type: EXPERIMENTAL
Intervention: New agents or regimens with intensive schedule
Number of subjects: 0
Study 6787637 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine HCl
Number of subjects: 29
Study 6787637 — intervention group
Group type: COMPARATOR
Intervention: Concomitant use of benztropine mesylate
Number of subjects: 29
Study 31220872 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norm feedback intervention (letter sent to GPs)
Number of subjects: 221
Study 27343197 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation (6609.0€)
Number of subjects: 433
Study 27343197 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric rehabilitation (7034.7€)
Number of subjects: 433
Study 27343197 — intervention group
Group type: COMPARATOR
Intervention: Control rehabilitation (4945.2€)
Number of subjects: 433
Study 27343197 — intervention group
Group type: COMPARATOR
Intervention: Control rehabilitation (13,438.4€)
Number of subjects: 433
Study 27343197 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation
Number of subjects: 433
Study 27343197 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation (36,356€, 51,018€)
Number of subjects: 433
Study 27343197 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation (15D-score 0.697)
Number of subjects: 433
Study 26620402 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced women-centred care approach to increase VBAC rates
Number of subjects: 16
Study 26620402 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 16
Study 24389434 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg daily plus pemetrexed 500 mg/m2 intravenously every 3 weeks
Number of subjects: 106
Study 24389434 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 75 mg/m2 intravenously every 3 weeks plus pemetrexed 500 mg/m2
Number of subjects: 106
Study 20810005 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure with response prevention (B-ERP)
Number of subjects: 135
Study 20810005 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure with response prevention (P-ERP)
Number of subjects: 135
Study 20810005 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training (RELAX)
Number of subjects: 135
Study 20810005 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure treatments (B-ERP and P-ERP)
Number of subjects: 135
Study 20810005 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 135
Study 18235425 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nasal dose of testosterone; administered in a double-blind, placebo-controlled, crossover manner.
Number of subjects: 0
Study 18235425 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group); administered in a double-blind, placebo-controlled, crossover manner.
Number of subjects: 0
Study 16581480 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time 3-dimensional echocardiography (RT3DE)
Number of subjects: 215
Study 16581480 — intervention group
Group type: EXPERIMENTAL
Intervention: RT3DE
Number of subjects: 215
Study 15329381 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-narrow incisor form
Number of subjects: 85
Study 15329381 — intervention group
Group type: COMPARATOR
Intervention: Short-wide incisor form
Number of subjects: 85
Study 15329381 — intervention group
Group type: COMPARATOR
Intervention: High responder subjects
Number of subjects: 85
Study 15329381 — intervention group
Group type: COMPARATOR
Intervention: Low responder subjects
Number of subjects: 85
Study 11520650 — intervention group
Group type: EXPERIMENTAL
Intervention: SAQ-UK (Seattle Angina Questionnaire - UK version)
Number of subjects: 959
Study 11520650 — intervention group
Group type: EXPERIMENTAL
Intervention: SAQ-UK
Number of subjects: 959
Study 9497467 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% apraclonidine
Number of subjects: 17
Study 8402842 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual inflation protocol
Number of subjects: 103
Study 8402842 — intervention group
Group type: COMPARATOR
Intervention: Rapid inflation protocol
Number of subjects: 103
Study 3781703 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 10
Study 3781703 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (400 mcg)
Number of subjects: 10
Study 3781703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 28635082 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribal Turning Point (TTP) intervention, 12 group classes and 5 individual sessions
Number of subjects: 62
Study 27225436 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine specific gravity (USG)
Number of subjects: 313
Study 27225436 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine color
Number of subjects: 313
Study 27225436 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine osmolality
Number of subjects: 313
Study 27225436 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine cloudiness
Number of subjects: 313
Study 27225436 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional dipstick measures
Number of subjects: 313
Study 27225436 — intervention group
Group type: EXPERIMENTAL
Intervention: Ability to provide a urine sample
Number of subjects: 313
Study 27225436 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of a random urine sample
Number of subjects: 313
Study 27225436 — intervention group
Group type: COMPARATOR
Intervention: Reference standard: serum osmolality
Number of subjects: 313
Study 23574529 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 5-μg twice daily
Number of subjects: 79
Study 23574529 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 10-μg twice daily
Number of subjects: 79
Study 23574529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 22051148 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-875 400 mg
Number of subjects: 0
Study 22051148 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-875 100 mg
Number of subjects: 0
Study 22051148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19953660 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention group
Number of subjects: 67
Study 18676932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cormet 2000 Hip Resurfacing
Number of subjects: 337
Study 18676932 — intervention group
Group type: COMPARATOR
Intervention: Total Hip Arthroplasty
Number of subjects: 337
Study 16457083 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2), 45 minutes daily for 10 days
Number of subjects: 26
Study 16457083 — intervention group
Group type: COMPARATOR
Intervention: Control group received hyperbaric air for 10 days, followed by HBO2
Number of subjects: 26
Study 12859697 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 20 mg/week
Number of subjects: 630
Study 12859697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 630
Study 10849263 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-α) 3 or 5 million units (MU) three times weekly (t.i.w.) for 3 months, intensified to daily therapy for those with detectable HCV RNA at 3 months.
Number of subjects: 222
Study 10849263 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha (IFN-α) three times weekly (t.i.w.) for 3 months (control group).
Number of subjects: 222
Study 8646959 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior sacral roots stimulator implants
Number of subjects: 8
Study 1324555 — intervention group
Group type: EXPERIMENTAL
Intervention: norgestimate triphasic (Ortho Tri‐Cyclen, Tri‐Ciles)
Number of subjects: 66
Study 1324555 — intervention group
Group type: EXPERIMENTAL
Intervention: levonorgestrel triphasic (Triphasi)
Number of subjects: 66
Study 6401927 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethindrone oral contraceptive
Number of subjects: 21
Study 6401927 — intervention group
Group type: EXPERIMENTAL
Intervention: Norgestrel oral contraceptive
Number of subjects: 21
Study 6401927 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Norethindrone vs Norgestrel
Number of subjects: 21
Study 31742809 — intervention group
Group type: EXPERIMENTAL
Intervention: Video discharge instructions
Number of subjects: 219
Study 31742809 — intervention group
Group type: COMPARATOR
Intervention: Paper handout discharge instructions
Number of subjects: 219
Study 30413727 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline drinking water (pH ≈ 9)
Number of subjects: 29
Study 30413727 — intervention group
Group type: COMPARATOR
Intervention: Neutral drinking water (pH ≈ 7)
Number of subjects: 29
Study 27799239 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary food supplements and dietary counselling
Number of subjects: 1804
Study 24373063 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 99
Study 24373063 — intervention group
Group type: COMPARATOR
Intervention: Sulphonylurea
Number of subjects: 99
Study 21703973 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical budesonide mouthwash (3 mg/10 mL) applied for 5 or 10 minutes, 2 or 3 times daily
Number of subjects: 0
Study 19622714 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg qd
Number of subjects: 30
Study 19622714 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg qd
Number of subjects: 30
Study 19622714 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of alogliptin and pioglitazone
Number of subjects: 30
Study 19622714 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide 5 mg
Number of subjects: 30
Study 19622714 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg qd with glyburide
Number of subjects: 30
Study 17484215 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV-6/11/16/18 vaccine
Number of subjects: 1781
Study 17484215 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 1781
Study 15708173 — intervention group
Group type: COMPARATOR
Intervention: Cerivastatin (C)
Number of subjects: 25
Study 15708173 — intervention group
Group type: COMPARATOR
Intervention: Coenzyme Q(10) (CoQ(10))
Number of subjects: 25
Study 15708173 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (Cerivastatin + CoQ(10))
Number of subjects: 25
Study 11973450 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS (Near-Infrared Spectroscopy)
Number of subjects: 0